Cargando…

SDPS-23 CUMULATIVE TUMOR VOLUME THRESHOLD CORRELATES WITH NEUROCOGNITIVE IMPAIRMENT IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES

OBJECTIVE: To explore the basic situation of cognitive function in patients with initial state of brain metastasis and the potential factors affecting cognitive function, so as to find the critical value of cumulative tumor volume leading to cognitive dysfunction. METHODS: A total of 284 patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhen, Junjie, Cao, Xiangyi, Wen, Lei, Wang, Hui, Lai, Mingyao, Cai, Linbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402384/
http://dx.doi.org/10.1093/noajnl/vdad070.079
_version_ 1785084864671776768
author Zhen, Junjie
Cao, Xiangyi
Wen, Lei
Wang, Hui
Lai, Mingyao
Cai, Linbo
author_facet Zhen, Junjie
Cao, Xiangyi
Wen, Lei
Wang, Hui
Lai, Mingyao
Cai, Linbo
author_sort Zhen, Junjie
collection PubMed
description OBJECTIVE: To explore the basic situation of cognitive function in patients with initial state of brain metastasis and the potential factors affecting cognitive function, so as to find the critical value of cumulative tumor volume leading to cognitive dysfunction. METHODS: A total of 284 patients who were newly diagnosed with brain metastases and underwent cognitive testing before radiotherapy in Guangdong Sanjiu Brain Hospital from 2016 to 2022 were retrospectively analyzed. The basic demographic information of the patients, KPS at the time of initial diagnosis, the number of brain metastases, the cumulative tumor volume, and the cognitive function test data before treatment were organized. RESULTS: The cognitive impairment occurred in 100/284 patients (the criteria for cognitive impairment is that at least two of the eight sub-tests are less than 1.5 standard deviation or at least one is less than 2 standard deviations). Multivariate analysis showed that the number of tumors was not a factor in cognitive dysfunction. Age, gender, KPS, educational level, and cumulative tumor volume were risk factors affecting cognitive function. The cumulative tumor volume cut-off value for MOCA, HVLT-R immediate memory, HVLT-R delayed memory, VFT, TMT-A, and TMT-B cognitive impairment were 13.608, 13.125, 11.070, 14.523, 11.070, and 11.113 cc, respectively, while cut-off value for SDMT and TOL were 5.435 and 4.528 cc, respectively. CONCLUSIONS: Before treatment, cognitive impairment of brain metastases had no significant correlation with the number of metastases but had a significant correlation with the cumulative tumor volume. The cumulative tumor volume cut-off value involving overall cognitive dysfunction, memory dysfunction, speech dysfunction, and decreased thinking speed is between 11-14.5 cc, and the cumulative tumor volume critical threshold involving executive dysfunction and computational dysfunction is between 4.5-5.5 cc.
format Online
Article
Text
id pubmed-10402384
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104023842023-08-05 SDPS-23 CUMULATIVE TUMOR VOLUME THRESHOLD CORRELATES WITH NEUROCOGNITIVE IMPAIRMENT IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES Zhen, Junjie Cao, Xiangyi Wen, Lei Wang, Hui Lai, Mingyao Cai, Linbo Neurooncol Adv Final Category: Screening/Diagnostics/Prognostics OBJECTIVE: To explore the basic situation of cognitive function in patients with initial state of brain metastasis and the potential factors affecting cognitive function, so as to find the critical value of cumulative tumor volume leading to cognitive dysfunction. METHODS: A total of 284 patients who were newly diagnosed with brain metastases and underwent cognitive testing before radiotherapy in Guangdong Sanjiu Brain Hospital from 2016 to 2022 were retrospectively analyzed. The basic demographic information of the patients, KPS at the time of initial diagnosis, the number of brain metastases, the cumulative tumor volume, and the cognitive function test data before treatment were organized. RESULTS: The cognitive impairment occurred in 100/284 patients (the criteria for cognitive impairment is that at least two of the eight sub-tests are less than 1.5 standard deviation or at least one is less than 2 standard deviations). Multivariate analysis showed that the number of tumors was not a factor in cognitive dysfunction. Age, gender, KPS, educational level, and cumulative tumor volume were risk factors affecting cognitive function. The cumulative tumor volume cut-off value for MOCA, HVLT-R immediate memory, HVLT-R delayed memory, VFT, TMT-A, and TMT-B cognitive impairment were 13.608, 13.125, 11.070, 14.523, 11.070, and 11.113 cc, respectively, while cut-off value for SDMT and TOL were 5.435 and 4.528 cc, respectively. CONCLUSIONS: Before treatment, cognitive impairment of brain metastases had no significant correlation with the number of metastases but had a significant correlation with the cumulative tumor volume. The cumulative tumor volume cut-off value involving overall cognitive dysfunction, memory dysfunction, speech dysfunction, and decreased thinking speed is between 11-14.5 cc, and the cumulative tumor volume critical threshold involving executive dysfunction and computational dysfunction is between 4.5-5.5 cc. Oxford University Press 2023-08-04 /pmc/articles/PMC10402384/ http://dx.doi.org/10.1093/noajnl/vdad070.079 Text en © The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Final Category: Screening/Diagnostics/Prognostics
Zhen, Junjie
Cao, Xiangyi
Wen, Lei
Wang, Hui
Lai, Mingyao
Cai, Linbo
SDPS-23 CUMULATIVE TUMOR VOLUME THRESHOLD CORRELATES WITH NEUROCOGNITIVE IMPAIRMENT IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES
title SDPS-23 CUMULATIVE TUMOR VOLUME THRESHOLD CORRELATES WITH NEUROCOGNITIVE IMPAIRMENT IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES
title_full SDPS-23 CUMULATIVE TUMOR VOLUME THRESHOLD CORRELATES WITH NEUROCOGNITIVE IMPAIRMENT IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES
title_fullStr SDPS-23 CUMULATIVE TUMOR VOLUME THRESHOLD CORRELATES WITH NEUROCOGNITIVE IMPAIRMENT IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES
title_full_unstemmed SDPS-23 CUMULATIVE TUMOR VOLUME THRESHOLD CORRELATES WITH NEUROCOGNITIVE IMPAIRMENT IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES
title_short SDPS-23 CUMULATIVE TUMOR VOLUME THRESHOLD CORRELATES WITH NEUROCOGNITIVE IMPAIRMENT IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES
title_sort sdps-23 cumulative tumor volume threshold correlates with neurocognitive impairment in patients with newly diagnosed brain metastases
topic Final Category: Screening/Diagnostics/Prognostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402384/
http://dx.doi.org/10.1093/noajnl/vdad070.079
work_keys_str_mv AT zhenjunjie sdps23cumulativetumorvolumethresholdcorrelateswithneurocognitiveimpairmentinpatientswithnewlydiagnosedbrainmetastases
AT caoxiangyi sdps23cumulativetumorvolumethresholdcorrelateswithneurocognitiveimpairmentinpatientswithnewlydiagnosedbrainmetastases
AT wenlei sdps23cumulativetumorvolumethresholdcorrelateswithneurocognitiveimpairmentinpatientswithnewlydiagnosedbrainmetastases
AT wanghui sdps23cumulativetumorvolumethresholdcorrelateswithneurocognitiveimpairmentinpatientswithnewlydiagnosedbrainmetastases
AT laimingyao sdps23cumulativetumorvolumethresholdcorrelateswithneurocognitiveimpairmentinpatientswithnewlydiagnosedbrainmetastases
AT cailinbo sdps23cumulativetumorvolumethresholdcorrelateswithneurocognitiveimpairmentinpatientswithnewlydiagnosedbrainmetastases